|Original language||English (US)|
|Journal||Circulation: Cardiovascular Quality and Outcomes|
|State||Published - Mar 1 2018|
- Cardiovascular disease
- Drug-related side effects and adverse reactions
- Hydroxymethylglutaryl-CoA reductase inhibitors
- Nocebo effect
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry. / Navar, Ann Marie; Peterson, Eric D.; Li, Shuang et al.In: Circulation: Cardiovascular Quality and Outcomes, Vol. 11, No. 3, e004249, 01.03.2018.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry
AU - Navar, Ann Marie
AU - Peterson, Eric D.
AU - Li, Shuang
AU - Robinson, Jennifer G.
AU - Roger, Veronique L.
AU - Goldberg, Anne C.
AU - Virani, Salim
AU - Wilson, Peter W.F.
AU - Nanna, Michael G.
AU - Lee, L. Veronica
AU - Elassal, Joseph
AU - Wang, Tracy Y.
N1 - Funding Information: Dr Navar reports research support from Regeneron/Sanofi, Amgen, and Janssen Pharmaceuticals; acts as a consultant for Sanofi and Amgen; and also funded by National Institutes of Health (NIH) K01HL133416-01. Dr Peterson reports research support from Eli Lilly, Janssen, and Merck; and acts as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, and Sanofi Aventis. Dr Robinson reports re- search support from Amarin, Amgen, AstraZeneca, Eli Lilly, Esai, Glaxo-Smith Kline, Merck, Pfizer, Regeneron/Sanofi, and Takeda; and acts as a consultant for Amgen, Eli Lilly, Merck, Pfizer, and Regeneron/Sanofi. Dr Goldberg reports research support from Amarin, Amgen, Pfizer, Merck, Regeneron/ Sanofi, IONIS, Genzyme/Isis, and Regeneron; acts as a consultant for Optum Rx, Regeneron/Sanofi, and Esperion; and receives honorarium for editorial work Merck Manual. Dr Vi-rani reports research support from American Diabetes Association/American Heart Association/Veterans Affairs; receives honorarium from American College of Cardiology as the Associate Editor for Innovations, ACC.org; none of these are related to the topic of this work. Dr Lee reports employment with Sanofi. Dr Elassal reports employment with Regeneron. Dr Wang reports research support from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Glaxo SmithKline, Regeneron, and Sanofi; and acts as a consultant/advisory/education from Bristol Myers Squibb, Astra Zeneca, Ali Lilly, and Premier, Inc. The other authors report no conflicts. Funding Information: This study was supported by Sanofi Pharmaceuticals and Re-generon Pharmaceuticals.
PY - 2018/3/1
Y1 - 2018/3/1
KW - Cardiovascular disease
KW - Drug-related side effects and adverse reactions
KW - Hydroxymethylglutaryl-CoA reductase inhibitors
KW - Nocebo effect
UR - http://www.scopus.com/inward/record.url?scp=85053398256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053398256&partnerID=8YFLogxK
U2 - 10.1161/CIRCOUTCOMES.117.004249
DO - 10.1161/CIRCOUTCOMES.117.004249
M3 - Article
C2 - 29545393
AN - SCOPUS:85053398256
SN - 1941-7713
VL - 11
JO - Circulation: Cardiovascular Quality and Outcomes
JF - Circulation: Cardiovascular Quality and Outcomes
IS - 3
M1 - e004249